Skip to main content

Table 5 Univariate and multivariate Cox regression analysis of SNPs associated with AML relapse-free survival (RFS)

From: Association of genetic polymorphisms in genes involved in Ara-C and dNTP metabolism pathway with chemosensitivity and prognosis of adult acute myeloid leukemia (AML)

Genotype n Mean ± SE (day) Median (range, day) HR (95% CI) P HR (95% CI)a P a
NME1 rs3760468
 AA 113 1058 ± 202 751 (294–1208) 1.00 (reference)   1.00 (reference)  
 AT 121 1163 ± 212 894 (378–1410) 0.946 (0.657–1.362) 0.764 1.027 (0.709–1.488) 0.887
 TT 39 655 ± 207 357 (285–429) 1.703 (1.070–2.709) 0.025 1.744 (1.085–2.801) 0.022
 AA+AT 234 1110 ± 149 761 (379–1143) 1.00 (reference)   1.00 (reference)  
 TT 39 655 ± 207 357 (285–429) 1.752 (1.142–2.686) 0.009 1.854 (1.197–2.871) 0.006
NME1 rs2302254
 CC 169 941 ± 129 724 (4484–964) 1.00 (reference)   1.00 (reference)  
 CT 87 1324 ± 266 1282 (516–2048) 0.770 (0.526–1.126) 0.177 0.728 (0.494–1.071) 0.107
 TT 22 581 ± 253 373 (286–460) 1.756 (1.014–3.042) 0.044 1.688 (0.973–2.928) 0.062
 CC+CT 256 1111 ± 156 760 (398–1122) 1.00 (reference)   1.00 (reference)  
 TT 22 581 ± 253 373 (286–460) 1.912 (1.117–3.272) 0.016 1.878 (1.096–3.217) 0.022
NME2 rs3744660
 GG 191 987 ± 124 751 (397–1105) 1.00 (reference)   1.00 (reference)  
 AG 71 1239 ± 283 976 (186–1766) 0.929 (0.627–1.377) 0.714 0.958 (0.644–1.425) 0.832
 AA 12 382 ± 116 373 (95–651) 2.087 (1.051–4.145) 0.036 2.224 (1.114–4.444) 0.024
 GG+AG 262 1136 ± 157 760 (399–1121) 1.00 (reference)   1.00 (reference)  
 AA 12 382 ± 116 373 (95–651) 2.127 (1.078–4.194) 0.026 2.250 (1.135–4.460) 0.020
RRM2 rs1130609
 TT 123 1126 ± 208 751 (368–1134) 1.00 (reference)   1.00 (reference)  
 GT 125 1129 ± 216 724 (209–1239) 1.561 (0.692–1.386) 0.907 0.926 (0.651–1.317) 0.668
 GG 29 679 ± 272 371 (200–542) 1.561 (0.900–2.707) 0.113 1.437 (0.825–2.501) 0.200
 TT+GT 248 1127 ± 159 729 (381–1077) 1.00 (reference)   1.00 (reference)  
 GG 29 679 ± 272 371 (200–542) 1.577 (0.935–2.660) 0.085 1.493 (0.882–2.528) 0.136
  1. aAdjusted for risk stratification, WBC count, and allo-SCT